Lilly, Gilead lead pharma’s M&A boom

FierceBiotechAntibodies that stop measles from stabbing cells could become new treatments for the surging virus, study suggests

FierceBiotechBeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial

Endpoints NewsEntrada stock falls on Duchenne data; Wegovy expands access

CellVirological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia

CellAffinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections

CellMulti-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome

FierceBiotechBlackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication

FierceBiotechFDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?

BioWorldFirst measles treatment advances as vaccination rates drop

FierceBiotechAscendis axes IL-2 program in retreat from oncology expansion

PharmaVoiceNovo hikes guidance on Wegovy pill’s fast sales start

Endpoints NewsAmgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany